Stockreport

Disc Medicine: RALLY-MF Data Validates Pipeline Optionality [Seeking Alpha]

Disc Medicine, Inc.  (IRON) 
PDF Bitopertin's NDA is submitted, aiming for accelerated FDA approval; if successful, IRON transitions from R&D to commercial stage with significant revenue potential. P [Read more]